BPC 157 dosage chart

Reconstitution steps

1. 1Draw 2mL of bacteriostatic water into a sterile syringe.
2. 2Inject the water slowly down the inside wall of the 10MG BPC 157 vial.
3. 3Swirl gently until fully dissolved — do not shake.
4. 4Use a U-100 insulin syringe for accurate dosing.
5. 5Store reconstituted solution refrigerated at 2–8 °C, protected from light.

Spartan Peptides official protocol

All doses are 1–2x daily.

• Mixing guide: mix 10MG BPC 157 with 2mL BAC water.
• Concentration after mixing: 5 mg/mL.
• Recommended dosage: 250mcg – 500mcg per dose.
• Injection frequency: 1–2x daily.
• Use an insulin syringe (U-100) for accurate dosing.

Reported research focus

Research purposes only. Premium quality. Built on legacy. Backed by science.

• Supports tissue repair*
• Reduces inflammation*
• Supports joint & tendon health*
• Supports recovery*

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• BPC-157 human data are preliminary; clinical decisions should involve qualified healthcare providers.

How This Works

BPC-157 is a synthetic peptide corresponding to a partial sequence of human gastric juice protein. Preclinical studies suggest it modulates nitric oxide pathways and growth-factor expression to promote angiogenesis and collagen deposition in damaged tissues. Animal models report accelerated healing of gut, tendon, ligament, and muscle injuries. A Phase I oral safety trial has been completed, and a small human case series reported improvements following intra-articular administration; however, large-scale controlled human efficacy data are not yet available.

Potential Benefits & Side Effects

Observations from preclinical and early clinical literature.

• Supports tissue repair in gut, tendon, muscle, and skin injury models (animal data).
• Demonstrates anti-inflammatory and cytoprotective properties in preclinical settings.
• Phase I safety studies report good tolerability with no serious adverse events at tested doses.
• Occasional mild injection-site reactions (redness, itch) may occur with subcutaneous administration.
• Long-term human safety and efficacy remain under investigation.

Lifestyle Factors

Complementary strategies for best outcomes.

• Support recovery with adequate protein intake and micronutrient-rich foods.
• Balance activity and rest to allow tissue adaptation without overuse.
• Prioritize sleep and stress management to enhance natural healing processes.
• Consult qualified healthcare providers for injury-specific rehabilitation guidance.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

• Clean the vial stopper and skin with alcohol; allow to dry.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
• Do not aspirate for subcutaneous injections; inject slowly and steadily.
• Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
• Discard used syringes immediately in a sharps container per WHO guidelines.

important-note

This content is for educational purposes only and is not medical advice, diagnosis, or treatment. BPC-157 remains investigational with limited human clinical data. For research use only. Not for human consumption.

BPC 157 dosage FAQs